Posted by Michael Wonder on 15 Jan 2019
Would drug price controls kill innovation?
14 January 2019 - Affordability doesn’t need to come at the expense of innovation.
Regarding your editorial “The Drug Price-Control Threat” (Jan. 8): Our nation’s prescription-drug system lacks transparency and competition, allowing brand-name pharmaceutical companies to maintain their monopolies and price gouge patients.
Affordability doesn’t need to come at the expense of innovation. There are bipartisan, market-based solutions, such as requiring drugmakers to disclose list prices in direct-to-consumer advertising and making it easier for generic and biosimilar drugs to enter the marketplace.
